Cargando…

Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy

Dendritic cell (DC) immunotherapy is capable of generating tumour-specific immune responses. Different maturation strategies were previously tested to obtain DC capable of anti-cancer responses in vitro, usually with limited clinical benefit. Mutual comparison of currently used maturation strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Vopenkova, Katerina, Mollova, Klara, Buresova, Ivana, Michalek, Jaroslav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118250/
https://www.ncbi.nlm.nih.gov/pubmed/22882679
http://dx.doi.org/10.1111/j.1582-4934.2012.01614.x
_version_ 1782328812914081792
author Vopenkova, Katerina
Mollova, Klara
Buresova, Ivana
Michalek, Jaroslav
author_facet Vopenkova, Katerina
Mollova, Klara
Buresova, Ivana
Michalek, Jaroslav
author_sort Vopenkova, Katerina
collection PubMed
description Dendritic cell (DC) immunotherapy is capable of generating tumour-specific immune responses. Different maturation strategies were previously tested to obtain DC capable of anti-cancer responses in vitro, usually with limited clinical benefit. Mutual comparison of currently used maturation strategies and subsequent complex evaluation of DC functions and their stimulatory capacity on T cells was performed in this study to optimize the DC vaccination strategy for further clinical application. DC were generated from monocytes using granulocyte–macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, pulsed with whole tumour cell lysate and then matured with one of five selected maturation strategies or cultured without additional maturation stimulus. DC were characterized with regard to their surface marker expression, cytokine profiles, migratory capacity, allogeneic and autologous T cell stimulatory capacity as well as their specific cytotoxicity against tumour antigens. We were able to demonstrate extensive variability among different maturation strategies currently used in DC immunotherapeutic protocols that may at least partially explain limited clinical benefit of some clinical trials with such DC. We identified DC matured with interferon-γ and lipopolysaccharide as the most attractive candidate for future clinical trials in cancer immunotherapy.
format Online
Article
Text
id pubmed-4118250
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-41182502015-03-25 Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy Vopenkova, Katerina Mollova, Klara Buresova, Ivana Michalek, Jaroslav J Cell Mol Med Original Articles Dendritic cell (DC) immunotherapy is capable of generating tumour-specific immune responses. Different maturation strategies were previously tested to obtain DC capable of anti-cancer responses in vitro, usually with limited clinical benefit. Mutual comparison of currently used maturation strategies and subsequent complex evaluation of DC functions and their stimulatory capacity on T cells was performed in this study to optimize the DC vaccination strategy for further clinical application. DC were generated from monocytes using granulocyte–macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, pulsed with whole tumour cell lysate and then matured with one of five selected maturation strategies or cultured without additional maturation stimulus. DC were characterized with regard to their surface marker expression, cytokine profiles, migratory capacity, allogeneic and autologous T cell stimulatory capacity as well as their specific cytotoxicity against tumour antigens. We were able to demonstrate extensive variability among different maturation strategies currently used in DC immunotherapeutic protocols that may at least partially explain limited clinical benefit of some clinical trials with such DC. We identified DC matured with interferon-γ and lipopolysaccharide as the most attractive candidate for future clinical trials in cancer immunotherapy. BlackWell Publishing Ltd 2012-11 2012-10-29 /pmc/articles/PMC4118250/ /pubmed/22882679 http://dx.doi.org/10.1111/j.1582-4934.2012.01614.x Text en © 2012 The Authors Journal of Cellular and Molecular Medicine © 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
spellingShingle Original Articles
Vopenkova, Katerina
Mollova, Klara
Buresova, Ivana
Michalek, Jaroslav
Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
title Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
title_full Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
title_fullStr Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
title_full_unstemmed Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
title_short Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
title_sort complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118250/
https://www.ncbi.nlm.nih.gov/pubmed/22882679
http://dx.doi.org/10.1111/j.1582-4934.2012.01614.x
work_keys_str_mv AT vopenkovakaterina complexevaluationofhumanmonocytederiveddendriticcellsforcancerimmunotherapy
AT mollovaklara complexevaluationofhumanmonocytederiveddendriticcellsforcancerimmunotherapy
AT buresovaivana complexevaluationofhumanmonocytederiveddendriticcellsforcancerimmunotherapy
AT michalekjaroslav complexevaluationofhumanmonocytederiveddendriticcellsforcancerimmunotherapy